{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:23:10Z","timestamp":1792110190881,"version":"4.4.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/nm.3159","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T15:10:06Z","timestamp":1367939406000},"page":"557-566","source":"Crossref","is-referenced-by-count":1953,"title":["PPAR\u03b3 signaling and metabolism: the good, the bad and the future"],"prefix":"10.1038","volume":"19","author":[{"given":"Maryam","family":"Ahmadian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myoung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasun","family":"Hah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette R","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"BFnm3159_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nm1025","volume":"10","author":"RM Evans","year":"2004","unstructured":"Evans, R.M., Barish, G.D. & Wang, Y.X. PPARs and the complex journey to obesity. Nat. Med. 10, 355\u2013361 (2004).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1172\/JCI27955","volume":"116","author":"GD Barish","year":"2006","unstructured":"Barish, G.D., Narkar, V.A. & Evans, R.M. PPAR\u03b4: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590\u2013597 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","volume":"23","author":"L Poulsen","year":"2012","unstructured":"Poulsen, L., Siersbaek, M. & Mandrup, S. PPARs: fatty acid sensors controlling metabolism. Semin. Cell Dev. Biol. 23, 631\u2013639 (2012).","journal-title":"Semin. Cell Dev. Biol."},{"key":"BFnm3159_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","volume":"83","author":"BM Forman","year":"1995","unstructured":"Forman, B.M. et al. 15-Deoxy-\u03b4 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR\u03b3. Cell 83, 803\u2013812 (1995).","journal-title":"Cell"},{"key":"BFnm3159_CR5","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","volume":"94","author":"BM Forman","year":"1997","unstructured":"Forman, B.M., Chen, J. & Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors \u03b1 and \u03b4. Proc. Natl. Acad. Sci. USA 94, 4312\u20134317 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1749-6632.1996.tb18621.x","volume":"804","author":"BM Forman","year":"1996","unstructured":"Forman, B.M., Chen, J. & Evans, R.M. The peroxisome proliferator-activated receptors: ligands and activators. Ann. NY Acad. Sci. 804, 266\u2013275 (1996).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnm3159_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz, P. & Spiegelman, B.M. Fat and beyond: the diverse biology of PPAR\u03b3. Annu. Rev. Biochem. 77, 289\u2013312 (2008).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnm3159_CR8","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1371\/journal.pgen.0030064","volume":"3","author":"G Medina-Gomez","year":"2007","unstructured":"Medina-Gomez, G. et al. PPAR\u03b32 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64 (2007).","journal-title":"PLoS Genet."},{"key":"BFnm3159_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.2042-7158.2011.01366.x","volume":"64","author":"N Saraf","year":"2012","unstructured":"Saraf, N., Sharma, P.K., Mondal, S.C., Garg, V.K. & Singh, A.K. Role of PPAR\u03b32 transcription factor in thiazolidinedione-induced insulin sensitization. J. Pharm. Pharmacol. 64, 161\u2013171 (2012).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFnm3159_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/wsbm.137","volume":"3","author":"M Vacca","year":"2011","unstructured":"Vacca, M., Degirolamo, C., Mariani-Costantini, R., Palasciano, G. & Moschetta, A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 562\u2013587 (2011).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"BFnm3159_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1517\/14740338.2012.691963","volume":"11","author":"J Kung","year":"2012","unstructured":"Kung, J. & Henry, R.R. Thiazolidinedione safety. Expert Opin. Drug Saf. 11, 565\u2013579 (2012).","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnm3159_CR12","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457\u20132471 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3159_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2010.920","volume":"304","author":"DJ Graham","year":"2010","unstructured":"Graham, D.J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. J. Am. Med. Assoc. 304, 411\u2013418 (2010).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnm3159_CR14","unstructured":"European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. \u3008 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/09\/news_detail_001119.jsp \u3009 (2010)."},{"key":"BFnm3159_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","volume":"155","author":"R Wilcox","year":"2008","unstructured":"Wilcox, R., Kupfer, S. & Erdmann, E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am. Heart J. 155, 712\u2013717 (2008).","journal-title":"Am. Heart J."},{"key":"BFnm3159_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff, A.M., Wolski, K., Nicholls, S.J. & Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J. Am. Med. Assoc. 298, 1180\u20131188 (2007).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnm3159_CR17","doi-asserted-by":"publisher","first-page":"e3645","DOI":"10.1136\/bmj.e3645","volume":"344","author":"L Azoulay","year":"2012","unstructured":"Azoulay, L. et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. Br. Med. J. 344, e3645 (2012).","journal-title":"Br. Med. J."},{"key":"BFnm3159_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","volume":"55","author":"A Neumann","year":"2012","unstructured":"Neumann, A. et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55, 1953\u20131962 (2012).","journal-title":"Diabetologia"},{"key":"BFnm3159_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature10383","volume":"477","author":"JH Choi","year":"2011","unstructured":"Choi, J.H. et al. Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477\u2013481 (2011).","journal-title":"Nature"},{"key":"BFnm3159_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.2349","volume":"17","author":"KK Ryan","year":"2011","unstructured":"Ryan, K.K. et al. A role for central nervous system PPAR-\u03b3 in the regulation of energy balance. Nat. Med. 17, 623\u2013626 (2011).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nm.2332","volume":"17","author":"M Lu","year":"2011","unstructured":"Lu, M. et al. Brain PPAR-\u03b3 promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat. Med. 17, 618\u2013622 (2011).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature10998","volume":"485","author":"JW Jonker","year":"2012","unstructured":"Jonker, J.W. et al. A PPAR\u03b3-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391\u2013394 (2012).","journal-title":"Nature"},{"key":"BFnm3159_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","volume":"148","author":"PA Dutchak","year":"2012","unstructured":"Dutchak, P.A. et al. Fibroblast growth factor-21 regulates PPAR\u03b3 activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556\u2013567 (2012).","journal-title":"Cell"},{"key":"BFnm3159_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","volume":"79","author":"P Tontonoz","year":"1994","unstructured":"Tontonoz, P., Hu, E. & Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPAR\u03b32, a lipid-activated transcription factor. Cell 79, 1147\u20131156 (1994).","journal-title":"Cell"},{"key":"BFnm3159_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1101\/gad.10.8.974","volume":"10","author":"RP Brun","year":"1996","unstructured":"Brun, R.P. et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10, 974\u2013984 (1996).","journal-title":"Genes Dev."},{"key":"BFnm3159_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1097-2765(00)80209-9","volume":"4","author":"Y Barak","year":"1999","unstructured":"Barak, Y. et al. PPAR\u03b3 is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585\u2013595 (1999).","journal-title":"Mol. Cell"},{"key":"BFnm3159_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/science.1156232","volume":"322","author":"W Tang","year":"2008","unstructured":"Tang, W. et al. White fat progenitor cells reside in the adipose vasculature. Science 322, 583\u2013586 (2008).","journal-title":"Science"},{"key":"BFnm3159_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cmet.2011.05.012","volume":"14","author":"W Tang","year":"2011","unstructured":"Tang, W., Zeve, D., Seo, J., Jo, A.Y. & Graff, J.M. Thiazolidinediones regulate adipose lineage dynamics. Cell Metab. 14, 116\u2013122 (2011).","journal-title":"Cell Metab."},{"key":"BFnm3159_CR29","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1073\/pnas.0400356101","volume":"101","author":"T Imai","year":"2004","unstructured":"Imai, T. et al. Peroxisome proliferator-activated receptor \u03b3 is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. USA 101, 4543\u20134547 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR30","doi-asserted-by":"publisher","first-page":"15712","DOI":"10.1073\/pnas.2536828100","volume":"100","author":"W He","year":"2003","unstructured":"He, W. et al. Adipose-specific peroxisome proliferator-activated receptor \u03b3 knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA 100, 15712\u201315717 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR31","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1074\/jbc.272.8.5283","volume":"272","author":"AN Hollenberg","year":"1997","unstructured":"Hollenberg, A.N. et al. Functional antagonism between CCAAT\/enhancer binding protein-\u03b1 and peroxisome proliferator-activated receptor-\u03b3 on the leptin promoter. J. Biol. Chem. 272, 5283\u20135290 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR32","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2337\/diabetes.52.7.1655","volume":"52","author":"M Iwaki","year":"2003","unstructured":"Iwaki, M. et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52, 1655\u20131663 (2003).","journal-title":"Diabetes"},{"key":"BFnm3159_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/endo.134.1.8275942","volume":"134","author":"C Hofmann","year":"1994","unstructured":"Hofmann, C. et al. Altered gene expression for tumor necrosis factor-\u03b1 and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134, 264\u2013270 (1994).","journal-title":"Endocrinology"},{"key":"BFnm3159_CR34","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1074\/jbc.M808407200","volume":"284","author":"T Tomaru","year":"2009","unstructured":"Tomaru, T., Steger, D.J., Lefterova, M.I., Schupp, M. & Lazar, M.A. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor \u03b3 and CCAAT\/enhancer-binding proteins. J. Biol. Chem. 284, 6116\u20136125 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR35","first-page":"408","volume":"87","author":"AK Agarwal","year":"2002","unstructured":"Agarwal, A.K. & Garg, A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-\u03b3 gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87, 408\u2013411 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnm3159_CR36","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.2337\/diabetes.51.12.3586","volume":"51","author":"RA Hegele","year":"2002","unstructured":"Hegele, R.A., Cao, H., Frankowski, C., Mathews, S.T. & Leff, T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586\u20133590 (2002).","journal-title":"Diabetes"},{"key":"BFnm3159_CR37","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","volume":"52","author":"DB Savage","year":"2003","unstructured":"Savage, D.B. et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-\u03b3. Diabetes 52, 910\u2013917 (2003).","journal-title":"Diabetes"},{"key":"BFnm3159_CR38","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). J. Biol. Chem. 270, 12953\u201312956 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR39","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/cr.2012.94","volume":"22","author":"K Sun","year":"2012","unstructured":"Sun, K. & Scherer, P.E. The PPAR\u03b3-FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res. 22, 1416\u20131418 (2012).","journal-title":"Cell Res."},{"key":"BFnm3159_CR40","doi-asserted-by":"publisher","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","volume":"91","author":"SA Kliewer","year":"2010","unstructured":"Kliewer, S.A. & Mangelsdorf, D.J. Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 91, 254S\u2013257S (2010).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnm3159_CR41","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/MCB.20.6.2260-2268.2000","volume":"20","author":"DL Miller","year":"2000","unstructured":"Miller, D.L., Ortega, S., Bashayan, O., Basch, R. & Basilico, C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol. Cell Biol. 20, 2260\u20132268 (2000).","journal-title":"Mol. Cell Biol."},{"key":"BFnm3159_CR42","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc. Natl. Acad. Sci. USA 109, 3143\u20133148 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR43","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1210\/endo.142.3.8037","volume":"142","author":"JM Way","year":"2001","unstructured":"Way, J.M. et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor \u03b3 activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 1269\u20131277 (2001).","journal-title":"Endocrinology"},{"key":"BFnm3159_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tem.2009.06.002","volume":"20","author":"M Ahmadian","year":"2009","unstructured":"Ahmadian, M., Duncan, R.E. & Sul, H.S. The skinny on fat: lipolysis and fatty acid utilization in adipocytes. Trends Endocrinol. Metab. 20, 424\u2013428 (2009).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnm3159_CR45","doi-asserted-by":"publisher","first-page":"22504","DOI":"10.1073\/pnas.0912487106","volume":"106","author":"S Sugii","year":"2009","unstructured":"Sugii, S. et al. PPAR\u03b3 activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl. Acad. Sci. USA 106, 22504\u201322509 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR46","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1172\/JCI119839","volume":"100","author":"CF Burant","year":"1997","unstructured":"Burant, C.F. et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100, 2900\u20132908 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR47","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2337\/diabetes.52.6.1311","volume":"52","author":"JK Kim","year":"2003","unstructured":"Kim, J.K. et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP\/F-1 fatless mice. Diabetes 52, 1311\u20131318 (2003).","journal-title":"Diabetes"},{"key":"BFnm3159_CR48","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm956","volume":"9","author":"AL Hevener","year":"2003","unstructured":"Hevener, A.L. et al. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9, 1491\u20131497 (2003).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1172\/JCI17305","volume":"112","author":"AW Norris","year":"2003","unstructured":"Norris, A.W. et al. Muscle-specific PPAR\u03b3-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112, 608\u2013618 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR50","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/00365520802530861","volume":"44","author":"YM Nan","year":"2009","unstructured":"Nan, Y.M. et al. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand. J. Gastroenterol. 44, 358\u2013365 (2009).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnm3159_CR51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","volume":"51","author":"AB Mayerson","year":"2002","unstructured":"Mayerson, A.B. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797\u2013802 (2002).","journal-title":"Diabetes"},{"key":"BFnm3159_CR52","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","volume":"55","author":"G Musso","year":"2012","unstructured":"Musso, G., Cassader, M., Rosina, F. & Gambino, R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885\u2013904 (2012).","journal-title":"Diabetologia"},{"key":"BFnm3159_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3748\/wjg.14.22","volume":"14","author":"ER Kallwitz","year":"2008","unstructured":"Kallwitz, E.R., McLachlan, A. & Cotler, S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14, 22\u201328 (2008).","journal-title":"World J. Gastroenterol."},{"key":"BFnm3159_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hep.21661","volume":"46","author":"G Lutchman","year":"2007","unstructured":"Lutchman, G. et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46, 424\u2013429 (2007).","journal-title":"Hepatology"},{"key":"BFnm3159_CR55","doi-asserted-by":"publisher","first-page":"34268","DOI":"10.1074\/jbc.M300043200","volume":"278","author":"O Gavrilova","year":"2003","unstructured":"Gavrilova, O. et al. Liver peroxisome proliferator-activated receptor \u03b3 contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268\u201334276 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR56","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.2337\/diab.45.11.1572","volume":"45","author":"K Berkowitz","year":"1996","unstructured":"Berkowitz, K. et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45, 1572\u20131579 (1996).","journal-title":"Diabetes"},{"key":"BFnm3159_CR57","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1073\/pnas.96.20.11513","volume":"96","author":"M Higa","year":"1999","unstructured":"Higa, M. et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. USA 96, 11513\u201311518 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR58","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2337\/diabetes.51.3.676","volume":"51","author":"HI Kim","year":"2002","unstructured":"Kim, H.I. et al. Peroxisomal proliferator-activated receptor-\u03b3 upregulates glucokinase gene expression in beta-cells. Diabetes 51, 676\u2013685 (2002).","journal-title":"Diabetes"},{"key":"BFnm3159_CR59","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2337\/diabetes.49.9.1517","volume":"49","author":"HI Kim","year":"2000","unstructured":"Kim, H.I. et al. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49, 1517\u20131524 (2000).","journal-title":"Diabetes"},{"key":"BFnm3159_CR60","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1128\/MCB.23.20.7222-7229.2003","volume":"23","author":"ED Rosen","year":"2003","unstructured":"Rosen, E.D. et al. Targeted elimination of peroxisome proliferator-activated receptor \u03b3 in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell Biol. 23, 7222\u20137229 (2003).","journal-title":"Mol. Cell Biol."},{"key":"BFnm3159_CR61","doi-asserted-by":"publisher","first-page":"32462","DOI":"10.1074\/jbc.M801813200","volume":"283","author":"D Gupta","year":"2008","unstructured":"Gupta, D. et al. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor \u03b3 response element in the mouse pdx-1 promoter. J. Biol. Chem. 283, 32462\u201332470 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR62","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1196\/annals.1366.013","volume":"1088","author":"I Szatmari","year":"2006","unstructured":"Szatmari, I., Rajnavolgyi, E. & Nagy, L. PPAR\u03b3, a lipid-activated transcription factor as a regulator of dendritic cell function. Ann. NY Acad. Sci. 1088, 207\u2013218 (2006).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnm3159_CR63","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.bbalip.2007.02.005","volume":"1771","author":"L Sz\u00e9les","year":"2007","unstructured":"Sz\u00e9les, L., Torocsik, D. & Nagy, L. PPAR\u03b3 in immunity and inflammation: cell types and diseases. Biochim. Biophys. Acta 1771, 1014\u20131030 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm3159_CR64","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.immuni.2010.11.009","volume":"33","author":"A Szanto","year":"2010","unstructured":"Szanto, A. et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPAR\u03b3-regulated gene expression in macrophages and dendritic cells. Immunity 33, 699\u2013712 (2010).","journal-title":"Immunity"},{"key":"BFnm3159_CR65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0092-8674(00)81575-5","volume":"93","author":"P Tontonoz","year":"1998","unstructured":"Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A. & Evans, R.M. 5PPAR\u03b3 promotes monocyte\/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241\u2013252 (1998).","journal-title":"Cell"},{"key":"BFnm3159_CR66","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","volume":"23","author":"W Wahli","year":"2012","unstructured":"Wahli, W. & Michalik, L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23, 351\u2013363 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnm3159_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1043-2760(02)00668-9","volume":"13","author":"CH Lee","year":"2002","unstructured":"Lee, C.H. & Evans, R.M. Peroxisome proliferator-activated receptor-\u03b3 in macrophage lipid homeostasis. Trends Endocrinol. Metab. 13, 331\u2013335 (2002).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnm3159_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0092-8674(00)81574-3","volume":"93","author":"L Nagy","year":"1998","unstructured":"Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H. & Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR\u03b3. Cell 93, 229\u2013240 (1998).","journal-title":"Cell"},{"key":"BFnm3159_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/83336","volume":"7","author":"A Chawla","year":"2001","unstructured":"Chawla, A. et al. PPAR-\u03b3 dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7, 48\u201352 (2001).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR70","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1172\/JCI31561","volume":"117","author":"AL Hevener","year":"2007","unstructured":"Hevener, A.L. et al. Macrophage PPAR\u03b3 is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658\u20131669 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR71","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature05894","volume":"447","author":"JI Odegaard","year":"2007","unstructured":"Odegaard, J.I. et al. Macrophage-specific PPAR\u03b3 controls alternative activation and improves insulin resistance. Nature 447, 1116\u20131120 (2007).","journal-title":"Nature"},{"key":"BFnm3159_CR72","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.febslet.2011.05.007","volume":"585","author":"S Sugii","year":"2011","unstructured":"Sugii, S. & Evans, R.M. Epigenetic codes of PPAR\u03b3 in metabolic disease. FEBS Lett. 585, 2121\u20132128 (2011).","journal-title":"FEBS Lett."},{"key":"BFnm3159_CR73","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature11132","volume":"486","author":"D Cipolletta","year":"2012","unstructured":"Cipolletta, D. et al. PPAR-\u03b3 is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549\u2013543 (2012).","journal-title":"Nature"},{"key":"BFnm3159_CR74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","volume":"23","author":"B Cariou","year":"2012","unstructured":"Cariou, B., Charbonnel, B. & Staels, B. Thiazolidinediones and PPAR\u03b3 agonists: time for a reassessment. Trends Endocrinol. Metab. 23, 205\u2013215 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnm3159_CR75","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2337\/diabetes.52.9.2249","volume":"52","author":"PJ Larsen","year":"2003","unstructured":"Larsen, P.J. et al. Differential influences of peroxisome proliferator-activated receptors \u03b3 and -\u03b1 on food intake and energy homeostasis. Diabetes 52, 2249\u20132259 (2003).","journal-title":"Diabetes"},{"key":"BFnm3159_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.physbeh.2006.05.028","volume":"88","author":"JE Cecil","year":"2006","unstructured":"Cecil, J.E., Watt, P., Palmer, C.N. & Hetherington, M. Energy balance and food intake: the role of PPAR\u03b3 gene polymorphisms. Physiol. Behav. 88, 227\u2013233 (2006).","journal-title":"Physiol. Behav."},{"key":"BFnm3159_CR77","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1210\/en.2008-0899","volume":"150","author":"DA Sarruf","year":"2009","unstructured":"Sarruf, D.A. et al. Expression of peroxisome proliferator-activated receptor-\u03b3 in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150, 707\u2013712 (2009).","journal-title":"Endocrinology"},{"key":"BFnm3159_CR78","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12035-012-8259-8","volume":"46","author":"YC Chen","year":"2012","unstructured":"Chen, Y.C. et al. Peroxisome proliferator-activated receptor \u03b3 (PPAR-\u03b3) and neurodegenerative disorders. Mol. Neurobiol. 46, 114\u2013124 (2012).","journal-title":"Mol. Neurobiol."},{"key":"BFnm3159_CR79","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1755-5922.2010.00222.x","volume":"29","author":"PA Sarafidis","year":"2011","unstructured":"Sarafidis, P.A., Georgianos, P.I. & Lasaridis, A.N. PPAR-\u03b3 agonism for cardiovascular and renal protection. Cardiovasc. Ther. 29, 377\u2013384 (2011).","journal-title":"Cardiovasc. Ther."},{"key":"BFnm3159_CR80","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1073\/pnas.0501744102","volume":"102","author":"H Zhang","year":"2005","unstructured":"Zhang, H. et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor \u03b3 blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. USA 102, 9406\u20139411 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR81","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR82","doi-asserted-by":"publisher","first-page":"F540","DOI":"10.1152\/ajprenal.00306.2011","volume":"302","author":"E Borsting","year":"2012","unstructured":"Borsting, E., Cheng, V.P., Glass, C.K., Vallon, V. & Cunard, R. Peroxisome proliferator-activated receptor-\u03b3 agonists repress epithelial sodium channel expression in the kidney. Am. J. Physiol. Renal Physiol. 302, F540\u2013F551 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnm3159_CR83","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm1278","volume":"11","author":"Y Guan","year":"2005","unstructured":"Guan, Y. et al. Thiazolidinediones expand body fluid volume through PPAR\u03b3 stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11, 861\u2013866 (2005).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR84","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/hrt.2009.165969","volume":"95","author":"R Marfella","year":"2009","unstructured":"Marfella, R. et al. Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function. Heart 95, 1020\u20131022 (2009).","journal-title":"Heart"},{"key":"BFnm3159_CR85","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1172\/JCI30335","volume":"117","author":"NH Son","year":"2007","unstructured":"Son, N.H. et al. Cardiomyocyte expression of PPAR\u03b3 leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791\u20132801 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","volume":"97","author":"SZ Duan","year":"2005","unstructured":"Duan, S.Z., Ivashchenko, C.Y., Russell, M.W., Milstone, D.S. & Mortensen, R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-\u03b3 both induce cardiac hypertrophy in mice. Circ. Res. 97, 372\u2013379 (2005).","journal-title":"Circ. Res."},{"key":"BFnm3159_CR87","doi-asserted-by":"publisher","first-page":"867180","DOI":"10.1155\/2011\/867180","volume":"2011","author":"W Wei","year":"2011","unstructured":"Wei, W. & Wan, Y. Thiazolidinediones on PPAR\u03b3: the roles in bone remodeling. PPAR Res. 2011, 867180 (2011).","journal-title":"PPAR Res."},{"key":"BFnm3159_CR88","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1172\/JCI200419900","volume":"113","author":"T Akune","year":"2004","unstructured":"Akune, T. et al. PPAR\u03b3 insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113, 846\u2013855 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR89","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/nm1672","volume":"13","author":"Y Wan","year":"2007","unstructured":"Wan, Y., Chong, L.W. & Evans, R.M. PPAR-\u03b3 regulates osteoclastogenesis in mice. Nat. Med. 13, 1496\u20131503 (2007).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR90","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cell.2012.06.027","volume":"150","author":"L Qiang","year":"2012","unstructured":"Qiang, L. et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppar\u03b3. Cell 150, 620\u2013632 (2012).","journal-title":"Cell"},{"key":"BFnm3159_CR91","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/oby.2008.473","volume":"17","author":"O van Beekum","year":"2009","unstructured":"van Beekum, O., Fleskens, V. & Kalkhoven, E. Posttranslational modifications of PPAR-\u03b3: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17, 213\u2013219 (2009).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnm3159_CR92","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1126\/science.274.5295.2100","volume":"274","author":"E Hu","year":"1996","unstructured":"Hu, E., Kim, J.B., Sarraf, P. & Spiegelman, B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR\u03b3. Science 274, 2100\u20132103 (1996).","journal-title":"Science"},{"key":"BFnm3159_CR93","doi-asserted-by":"publisher","first-page":"10811","DOI":"10.1074\/jbc.272.16.10811","volume":"272","author":"HS Camp","year":"1997","unstructured":"Camp, H.S. & Tafuri, S.R. Regulation of peroxisome proliferator-activated receptor \u03b3 activity by mitogen-activated protein kinase. J. Biol. Chem. 272, 10811\u201310816 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR94","doi-asserted-by":"publisher","first-page":"31771","DOI":"10.1074\/jbc.271.50.31771","volume":"271","author":"B Zhang","year":"1996","unstructured":"Zhang, B. et al. Insulin- and mitogen-activated protein kinase\u2013mediated phosphorylation and activation of peroxisome proliferator-activated receptor \u03b3. J. Biol. Chem. 271, 31771\u201331774 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR95","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1210\/me.2005-0222","volume":"20","author":"I Iankova","year":"2006","unstructured":"Iankova, I. et al. Peroxisome proliferator-activated receptor \u03b3 recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol. Endocrinol. 20, 1494\u20131505 (2006).","journal-title":"Mol. Endocrinol."},{"key":"BFnm3159_CR96","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1128\/MCB.25.14.6065-6076.2005","volume":"25","author":"E Compe","year":"2005","unstructured":"Compe, E. et al. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol. Cell Biol. 25, 6065\u20136076 (2005).","journal-title":"Mol. Cell Biol."},{"key":"BFnm3159_CR97","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1056\/NEJM199810013391403","volume":"339","author":"M Ristow","year":"1998","unstructured":"Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W. & Kahn, C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953\u2013959 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3159_CR98","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1534-5807(03)00274-0","volume":"5","author":"SM Rangwala","year":"2003","unstructured":"Rangwala, S.M. et al. Genetic modulation of PPAR\u03b3 phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657\u2013663 (2003).","journal-title":"Dev. Cell"},{"key":"BFnm3159_CR99","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/35096019","volume":"2","author":"R Dhavan","year":"2001","unstructured":"Dhavan, R. & Tsai, L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749\u2013759 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFnm3159_CR100","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1074\/jbc.M805052200","volume":"284","author":"E Utreras","year":"2009","unstructured":"Utreras, E. et al. Tumor necrosis factor-\u03b1 regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J. Biol. Chem. 284, 2275\u20132284 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi, J.H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5. Nature 466, 451\u2013456 (2010).","journal-title":"Nature"},{"key":"BFnm3159_CR102","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1074\/jbc.M109.053942","volume":"285","author":"N Petrovic","year":"2010","unstructured":"Petrovic, N. et al. Chronic peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J. Biol. Chem. 285, 7153\u20137164 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1152\/physrev.00015.2003","volume":"84","author":"B Cannon","year":"2004","unstructured":"Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277\u2013359 (2004).","journal-title":"Physiol. Rev."},{"key":"BFnm3159_CR104","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cmet.2010.03.007","volume":"11","author":"J Nedergaard","year":"2010","unstructured":"Nedergaard, J. & Cannon, B. The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab. 11, 268\u2013272 (2010).","journal-title":"Cell Metab."},{"key":"BFnm3159_CR105","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbadis.2005.02.003","volume":"1740","author":"J Nedergaard","year":"2005","unstructured":"Nedergaard, J., Petrovic, N., Lindgren, E.M., Jacobsson, A. & Cannon, B. PPAR\u03b3 in the control of brown adipocyte differentiation. Biochim. Biophys. Acta 1740, 293\u2013304 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm3159_CR106","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cmet.2012.01.019","volume":"15","author":"H Ohno","year":"2012","unstructured":"Ohno, H., Shinoda, K., Spiegelman, B.M. & Kajimura, S. PPAR\u03b3 agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 15, 395\u2013404 (2012).","journal-title":"Cell Metab."},{"key":"BFnm3159_CR107","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1021\/cr2001355","volume":"111","author":"GS Harmon","year":"2011","unstructured":"Harmon, G.S., Lam, M.T. & Glass, C.K. PPARs and lipid ligands in inflammation and metabolism. Chem. Rev. 111, 6321\u20136340 (2011).","journal-title":"Chem. Rev."},{"key":"BFnm3159_CR108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11010-005-9052-z","volume":"286","author":"M Shimizu","year":"2006","unstructured":"Shimizu, M., Yamashita, D., Yamaguchi, T., Hirose, F. & Osumi, T. Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation. Mol. Cell Biochem. 286, 33\u201342 (2006).","journal-title":"Mol. Cell Biochem."},{"key":"BFnm3159_CR109","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nature03988","volume":"437","author":"G Pascual","year":"2005","unstructured":"Pascual, G. et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-\u03b3. Nature 437, 759\u2013763 (2005).","journal-title":"Nature"},{"key":"BFnm3159_CR110","doi-asserted-by":"publisher","first-page":"18527","DOI":"10.1074\/jbc.M001297200","volume":"275","author":"S Hauser","year":"2000","unstructured":"Hauser, S. et al. Degradation of the peroxisome proliferator-activated receptor \u03b3 is linked to ligand-dependent activation. J. Biol. Chem. 275, 18527\u201318533 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR111","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.1074\/jbc.M007894200","volume":"276","author":"KJ Waite","year":"2001","unstructured":"Waite, K.J., Floyd, Z.E., Arbour-Reily, P. & Stephens, J.M. Interferon-\u03b3\u2013induced regulation of peroxisome proliferator-activated receptor \u03b3 and STATs in adipocytes. J. Biol. Chem. 276, 7062\u20137068 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnm3159_CR112","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","volume":"591","author":"JS Lewis","year":"2005","unstructured":"Lewis, J.S. & Jordan, V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591, 247\u2013263 (2005).","journal-title":"Mutat. Res."},{"key":"BFnm3159_CR113","doi-asserted-by":"crossref","first-page":"pe9","DOI":"10.1126\/stke.2002.121.pe9","volume":"2002","author":"SM Rangwala","year":"2002","unstructured":"Rangwala, S.M. & Lazar, M.A. The dawn of the SPPARMs? Sci. STKE 2002, pe9 (2002).","journal-title":"Sci. STKE"},{"key":"BFnm3159_CR114","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.str.2011.10.018","volume":"20","author":"TS Hughes","year":"2012","unstructured":"Hughes, T.S. et al. Ligand and receptor dynamics contribute to the mechanism of graded PPAR\u03b3 agonism. Structure 20, 139\u2013150 (2012).","journal-title":"Structure"},{"key":"BFnm3159_CR115","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature07413","volume":"456","author":"V Chandra","year":"2008","unstructured":"Chandra, V. et al. Structure of the intact PPAR-\u03b3\u2013RXR\u2013nuclear receptor complex on DNA. Nature 456, 350\u2013356 (2008).","journal-title":"Nature"},{"key":"BFnm3159_CR116","doi-asserted-by":"publisher","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","volume":"91","author":"LS Higgins","year":"2010","unstructured":"Higgins, L.S. & Depaoli, A.M. Selective peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulation as a strategy for safer therapeutic PPAR\u03b3 activation. Am. J. Clin. Nutr. 91, 267S\u2013272S (2010).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnm3159_CR117","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1073\/pnas.0709279105","volume":"105","author":"LE Tavera-Mendoza","year":"2008","unstructured":"Tavera-Mendoza, L.E. et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc. Natl. Acad. Sci. USA 105, 8250\u20138255 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3159_CR118","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/nm.3009","volume":"18","author":"B Finan","year":"2012","unstructured":"Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847\u20131856 (2012).","journal-title":"Nat. Med."},{"key":"BFnm3159_CR119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/dmrr.715","volume":"23","author":"B Chappuis","year":"2007","unstructured":"Chappuis, B. et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab. Res. Rev. 23, 392\u2013399 (2007).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"BFnm3159_CR120","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.2337\/dc06-1903","volume":"30","author":"MA Deeg","year":"2007","unstructured":"Deeg, M.A. et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30, 2458\u20132464 (2007).","journal-title":"Diabetes Care"},{"key":"BFnm3159_CR121","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","volume":"28","author":"RB Goldberg","year":"2005","unstructured":"Goldberg, R.B. et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28, 1547\u20131554 (2005).","journal-title":"Diabetes Care"},{"key":"BFnm3159_CR122","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","volume":"278","author":"J Sakamoto","year":"2000","unstructured":"Sakamoto, J. et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278, 704\u2013711 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnm3159_CR123","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ahj.2012.06.023","volume":"164","author":"RS Rosenson","year":"2012","unstructured":"Rosenson, R.S., Wright, R.S., Farkouh, M. & Plutzky, J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am. Heart J. 164, 672\u2013680 (2012).","journal-title":"Am. Heart J."},{"key":"BFnm3159_CR124","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1463-1326.2010.01237.x","volume":"12","author":"R Rab\u00f8l","year":"2010","unstructured":"Rab\u00f8l, R. et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes. Metab. 12, 806\u2013814 (2010).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnm3159_CR125","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.phrs.2007.03.002","volume":"56","author":"P Balakumar","year":"2007","unstructured":"Balakumar, P., Rose, M., Ganti, S.S., Krishan, P. & Singh, M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res. 56, 91\u201398 (2007).","journal-title":"Pharmacol. Res."},{"key":"BFnm3159_CR126","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/386407a0","volume":"386","author":"R Mukherjee","year":"1997","unstructured":"Mukherjee, R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407\u2013410 (1997).","journal-title":"Nature"},{"key":"BFnm3159_CR127","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1210\/endo.139.6.6130","volume":"139","author":"A Sugawara","year":"1998","unstructured":"Sugawara, A. et al. Characterization of mouse retinoid X receptor (RXR)-\u03b2 gene promoter: negative regulation by tumor necrosis factor (TNF)-\u03b1. Endocrinology 139, 3030\u20133033 (1998).","journal-title":"Endocrinology"},{"key":"BFnm3159_CR128","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/jcp.23005","volume":"227","author":"AB Singh","year":"2012","unstructured":"Singh, A.B., Guleria, R.S., Nizamutdinova, I.T., Baker, K.M. & Pan, J. High glucose-induced repression of RAR\/RXR in cardiomyocytes is mediated through oxidative stress\/JNK signaling. J. Cell Physiol. 227, 2632\u20132644 (2012).","journal-title":"J. Cell Physiol."},{"key":"BFnm3159_CR129","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1172\/JCI38606","volume":"120","author":"B Lefebvre","year":"2010","unstructured":"Lefebvre, B. et al. Proteasomal degradation of retinoid X receptor \u03b1 reprograms transcriptional activity of PPAR\u03b3 in obese mice and humans. J. Clin. Invest. 120, 1454\u20131468 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnm3159_CR130","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cmet.2011.04.004","volume":"13","author":"R Singh","year":"2011","unstructured":"Singh, R. & Cuervo, A.M. Autophagy in the cellular energetic balance. Cell Metab. 13, 495\u2013504 (2011).","journal-title":"Cell Metab."},{"key":"BFnm3159_CR131","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cmet.2011.12.018","volume":"15","author":"R Zechner","year":"2012","unstructured":"Zechner, R. et al. FAT SIGNALS\u2014lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 15, 279\u2013291 (2012).","journal-title":"Cell Metab."},{"issue":"suppl. 4","key":"BFnm3159_CR132","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/ijo.2008.116","volume":"32","author":"DG Hardie","year":"2008","unstructured":"Hardie, D.G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond.) 32 (suppl. 4), S7\u2013S12 (2008).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"BFnm3159_CR133","doi-asserted-by":"publisher","first-page":"341671","DOI":"10.1155\/2010\/341671","volume":"2010","author":"I Takada","year":"2010","unstructured":"Takada, I., Kouzmenko, A.P. & Kato, S. PPAR-\u03b3 signaling crosstalk in mesenchymal stem cells. PPAR Res. 2010, 341671 (2010).","journal-title":"PPAR Res."},{"key":"BFnm3159_CR134","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.2337\/diabetes.51.10.2968","volume":"51","author":"JG Yu","year":"2002","unstructured":"Yu, J.G. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968\u20132974 (2002).","journal-title":"Diabetes"},{"key":"BFnm3159_CR135","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0022-2275(20)33479-9","volume":"40","author":"U Edvardsson","year":"1999","unstructured":"Edvardsson, U. et al. Rosiglitazone (BRL49653), a PPAR\u03b3-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid Res. 40, 1177\u20131184 (1999).","journal-title":"J. Lipid Res."},{"key":"BFnm3159_CR136","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/pmic.200300484","volume":"3","author":"JC Sanchez","year":"2003","unstructured":"Sanchez, J.C. et al. Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep\/lep mice. Proteomics 3, 1500\u20131520 (2003).","journal-title":"Proteomics"},{"key":"BFnm3159_CR137","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrg2795","volume":"11","author":"RD Hawkins","year":"2010","unstructured":"Hawkins, R.D., Hon, G.C. & Ren, B. Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11, 476\u2013486 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"BFnm3159_CR138","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1101\/gad.1709008","volume":"22","author":"MI Lefterova","year":"2008","unstructured":"Lefterova, M.I. et al. PPAR\u03b3 and C\/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22, 2941\u20132952 (2008).","journal-title":"Genes Dev."},{"key":"BFnm3159_CR139","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/MCB.01651-09","volume":"30","author":"MI Lefterova","year":"2010","unstructured":"Lefterova, M.I. et al. Cell-specific determinants of peroxisome proliferator-activated receptor \u03b3 function in adipocytes and macrophages. Mol. Cell Biol. 30, 2078\u20132089 (2010).","journal-title":"Mol. Cell Biol."},{"key":"BFnm3159_CR140","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/emboj.2011.65","volume":"30","author":"R Siersb\u00e6k","year":"2011","unstructured":"Siersb\u00e6k, R. et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 30, 1459\u20131472 (2011).","journal-title":"EMBO J."},{"key":"BFnm3159_CR141","doi-asserted-by":"publisher","first-page":"e4907","DOI":"10.1371\/journal.pone.0004907","volume":"4","author":"MS Hamza","year":"2009","unstructured":"Hamza, M.S. et al. De-novo identification of PPAR\u03b3\/RXR binding sites and direct targets during adipogenesis. PLoS ONE 4, e4907 (2009).","journal-title":"PLoS ONE"},{"key":"BFnm3159_CR142","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2164-12-152","volume":"12","author":"SF Schmidt","year":"2011","unstructured":"Schmidt, S.F. et al. Cross species comparison of C\/EBP\u03b1 and PPAR\u03b3 profiles in mouse and human adipocytes reveals interdependent retention of binding sites. BMC Genomics 12, 152 (2011).","journal-title":"BMC Genomics"},{"key":"BFnm3159_CR143","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4161\/trns.3.1.19302","volume":"3","author":"SF Schmidt","year":"2012","unstructured":"Schmidt, S.F., Jorgensen, M., Sandelin, A. & Mandrup, S. Cross-species ChIP-seq studies provide insights into regulatory strategies of PPAR\u03b3 in adipocytes. Transcription 3, 19\u201324 (2012).","journal-title":"Transcription"},{"key":"BFnm3159_CR144","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1093\/nar\/gks595","volume":"40","author":"AA S\u00e9randour","year":"2012","unstructured":"S\u00e9randour, A.A. et al. Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res. 40, 8255\u20138265 (2012).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3159","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:39:20Z","timestamp":1684435160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFnm3159"],"URL":"https:\/\/doi.org\/10.1038\/nm.3159","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}